A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers: The Canary Prostate Cancer Tissue Microarray.
Adv Anat Pathol., Jan;20(1):39-44 (2013)
Current status of focal primary therapy for prostate cancer.
Urol. Oncol., Nov;30(6):942-3 (2012)
Employing the Epigenetic Field Defect to Detect Prostate Cancer in Biopsy-Negative Patients.
J. Urol., Nov (2012)
Contemporary Grading for Prostate Cancer: Implications for Patient Care.
Eur. Urol., Oct (2012)
Advanced clinical States in prostate cancer.
Urol. Clin. North Am., Nov;39(4):561-71 (2012)
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy.
Clin. Cancer Res., Oct;18(19):5471-8 (2012)
The changing landscape of urologic oncology: initiating systemic therapies, interventional skills, and clinical trials. Introduction.
Urol. Oncol., 30(4 Suppl):S1 (2012 Jul-Aug)
Reply to circumcision unlikely to be associated with prostate cancer risk.
Cancer., Jun (2012)
Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial.
J. Clin. Endocrinol. Metab., Aug;97(8):2809-17 (2012)
J Natl Compr Canc Netw., Apr;10(4):502-35 (2012)
Circumcision and the risk of prostate cancer.
Cancer., Sep;118(18):4437-43 (2012)
The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: A multi-center randomized trial.
Urol. Oncol., Dec (2011)
Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.
Clin Adv Hematol Oncol., Jun;9(6):1-11; discussion 11-5 (2011)
J Natl Compr Canc Netw., Sep;9(9):960-77 (2011)
Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.
Cancer Epidemiol. Biomarkers Prev., Sep;20(9):1928-36 (2011)
Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity.
Genome Res., Sep;21(9):1450-61 (2011)
Hospital-level variation in the quality of urologic cancer surgery.
Cancer., Feb;118(4):987-96 (2012)
Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.
Am. J. Epidemiol., Jun;173(12):1419-28 (2011)
The effect of demographic and clinical factors on the relationship between BMI and PSA levels.
Prostate., Nov;71(15):1631-7 (2011)
Influence of publication of US and European prostate cancer screening trials on PSA testing practices.
J. Natl. Cancer Inst., Mar;103(6):520-3 (2011)
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.
Cancer Epidemiol. Biomarkers Prev., Apr;20(4):619-27 (2011)
Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.
J. Clin. Endocrinol. Metab., Feb;96(2):430-7 (2011)
Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen.
J. Urol., Dec;184(6):2303-7 (2010)
AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.
Prostate., Apr;71(5):498-506 (2011)
Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect.
Clin. Cancer Res., Nov;16(22):5414-23 (2010)
What happens after an elevated PSA test: the experience of 13,591 veterans.
J Gen Intern Med., Nov;25(11):1205-10 (2010)
Vitamin D pathway gene variants and prostate cancer prognosis.
Prostate., Sep;70(13):1448-60 (2010)
CYP17 polymorphisms and prostate cancer outcomes.
Prostate., Jul;70(10):1094-101 (2010)
Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality.
J. Urol., Jun;183(6):2213-8 (2010)
Male pattern baldness and prostate cancer risk in a population-based case-control study.
Cancer Epidemiol., Apr;34(2):131-5 (2010)
Association of hepsin gene variants with prostate cancer risk and prognosis.
Prostate., Jun;70(9):1012-9 (2010)
Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Am. J. Epidemiol., Mar;171(5):571-82 (2010)
Genetics: Prostate cancer risk stratification by genotype and PSA.
Nat Rev Urol., Dec;6(12):641-2 (2009)
Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Prostate., May;70(6):584-90 (2010)
Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort.
J. Urol., Dec;182(6):2702-7 (2009)
J. Urol., Dec;182(6):2720 (2009)
Effect of collecting duct histology on renal cell cancer outcome.
J. Urol., Dec;182(6):2595-9 (2009)
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.
Urology., Feb;75(2):407-13 (2010)
Correlation between selenium concentrations and glutathione peroxidase activity in serum and human prostate tissue.
Prostate., Nov;69(15):1635-42 (2009)
Evaluation of the 8q24 prostate cancer risk locus and MYC expression.
Cancer Res., Jul;69(13):5568-74 (2009)
Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Prostate., Sep;69(12):1303-11 (2009)
Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study.
Cancer., Jul;115(13):2863-71 (2009)
Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.
Urol. Oncol., 27(3):315-21 (2009 May-Jun)
New and novel markers for prostate cancer detection.
Curr Urol Rep., May;10(3):179-86 (2009)
Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer.
Transl Oncol., Mar;2(1):39-45 (2009)
A dietary intervention to elicit rapid and complex dietary changes for studies investigating the effects of diet on tissues collected during invasive surgical procedures.
J Am Diet Assoc., Mar;109(3):459-63 (2009)
Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.
Clin. Cancer Res., Jan;15(2):677-83 (2009)
Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.
Prostate., Mar;69(4):363-72 (2009)
Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Am. J. Epidemiol., Dec;168(12):1416-24 (2008)
Primary scrotal cancer: disease characteristics and increasing incidence.
Urology., Nov;72(5):1139-43 (2008)
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.
Urology., Dec;72(6):1298-302; discussion 1302-4 (2008)
Circulating microRNAs as stable blood-based markers for cancer detection.
Proc. Natl. Acad. Sci. U.S.A., Jul;105(30):10513-8 (2008)
Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer.
Urology., Sep;72(3):474-80 (2008)
The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy.
Cancer., Jun;112(11):2401-8 (2008)
Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.
J. Urol., May;179(5):1775-9 (2008)
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
Clin. Cancer Res., Jan;14(1):224-9 (2008)
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.
Clin. Chem., Jan;54(1):53-60 (2008)
Does RPLND improve outcomes in men with intermediate-risk and high-risk germ cell tumors?
Nat Clin Pract Urol., Dec;4(12):654-5 (2007)
Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.
J. Urol., Dec;178(6):2302-6; discussion 2307 (2007)
Low-fat, low-glycemic load diet and gene expression in human prostate epithelium: a feasibility study of using cDNA microarrays to assess the response to dietary intervention in target tissues.
Cancer Epidemiol. Biomarkers Prev., Oct;16(10):2150-4 (2007)
Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.
Cancer Causes Control., Feb;19(1):25-31 (2008)
Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Cancer Causes Control., Nov;18(9):931-7 (2007)
Trends in renal cancer surgery and patient provider characteristics associated with partial nephrectomy in the United States.
Urol. Oncol., 25(4):298-302 (2007 Jul-Aug)
Quality of life in young men after radical prostatectomy.
Prostate Cancer Prostatic Dis., 11(1):67-73 (2008)
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
J. Clin. Oncol., May;25(15):2035-41 (2007)
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Cancer Res., May;67(10):5033-41 (2007)
Role of post-chemotherapy surgery in germ cell tumors.
Urol. Clin. North Am., May;34(2):199-217; abstract ix (2007)
The basic biochemistry and molecular events of hormone therapy.
Curr Urol Rep., May;8(3):224-32 (2007)
Editorial comment on: marked gene transcript level alterations occur early during radical prostatectomy.
Eur. Urol., Feb;53(2):345-6 (2008)
Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.
Cancer., Mar;109(6):1192-202 (2007)
Incidence of primary urethral carcinoma in the United States.
Urology., Dec;68(6):1164-8 (2006)
Microarray analysis and tumor classification.
N. Engl. J. Med., Aug;355(9):960; author reply 960 (2006)
Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis.
Prostate., Oct;66(14):1535-41 (2006)
Incidence of testicular germ cell cancers in U.S. children: SEER program experience 1973 to 2000.
Urology., Aug;68(2):402-5; discussion 405 (2006)
Persistent intraprostatic androgen concentrations after medical castration in healthy men.
J. Clin. Endocrinol. Metab., Oct;91(10):3850-6 (2006)
Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder.
Cancer., Aug;107(4):721-8 (2006)
Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis.
J. Clin. Oncol., Aug;24(23):3763-70 (2006)
Statins and the risk of cancer.
JAMA., Jun;295(23):2721; author reply 2721-2 (2006)
Intermittent androgen deprivation: clinical experience and practical applications.
Urol. Clin. North Am., May;33(2):167-79, vi (2006)
Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites.
Am. J. Physiol. Endocrinol. Metab., May;290(5):E856-63 (2006)
Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.
Int. J. Urol., Nov;12(11):1012-3 (2005)
Editorial comment on "Treatment of nonretroperitoneal residual germ cell tumor masses".
Urol. Oncol., 23(6):439-40 (2005 Nov-Dec)
Prostate cancer in men using testosterone supplementation.
J. Urol., Aug;174(2):534-8; discussion 538 (2005)
Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Clin. Cancer Res., Sep;10(17):5808-14 (2004)
The increasing role of CAM in prostate cancer.
JAAPA., Mar;17(3):37-40, 43-4 (2004)
Does the who and how of surgery in bladder cancer matter?
J. Clin. Oncol., Jul;22(14):2762-4 (2004)
The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma.
Clin Prostate Cancer., Sep;2(2):119-26 (2003)
Endourological treatment of ureteroenteric strictures: efficacy of Acucise endoureterotomy.
J. Urol., Sep;162(3 Pt 1):696-8 (1999)
Serum percent free prostate-specific antigen in metastatic prostate cancer.
Urology., Sep;52(3):366-71 (1998)
Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma.
J. Urol., Jul;160(1):77-81; discussion 81-2 (1998)